In a July 22 research note, H.C. Wainwright & Co. LLC Healthcare Analysts Yi Chen, Ph.D. CFA and Raghuram Selvaraju, Ph.D. advised that the U.S. Patent and Trademark Office (USPTO) recently issued a Notice of Allowance for clinical-stage biotechnology company Anixa Biosciences Inc. (ANIX: NASDAQ) novel breast cancer vaccine technology.
The new patent is an extension of the patent originally granted patent and it covers additional intellectual property (IP) specifically related to breast cancer vaccine technology. The analysts stated that the awarding of the additional patent strengthens Anixa Biosciences' overall IP portfolio and commercial prospects for this particular asset.
The report from H.C. Wainwright & Co. indicated that "the novel breast cancer vaccine has the potential to prevent triple-negative breast cancer (TNBC) and other forms of breast cancer that express alpha-lactalbumin." The research firm noted that in light of this development it is reiterating its Buy rating and $11 price target on the company.
The report mentioned that Anixa Biosciences initiated a Phase 1 multiple-ascending dose (MAD) breast cancer vaccine study at the Cleveland Clinic in October 2021. The trial was designed to enroll 18-24 high-risk patients who had previously undergone treatment for early-stage TNBC within the preceding three years. The trial was structured for participants to receive three vaccinations, two weeks apart, in order to ascertain the Maximum Tolerated Dose (MTD). H.C. Wainwright said that it expects the data from the vaccine study to be available in H2/22.
The analysts remarked, "We believe this large molecule prophylactic vaccine has the potential to train the immune system to target retired tissue-specific protein α-lactalbumin—referred to as a "retired" self-antigen—localized to TNBC tumor cells."
Anixa is a clinical-stage biotechnology company based in San Jose, Calif. The firm is currently developing several research and clinical programs focused on cancer and infectious diseases.
H.C. Wainwright & Co. advised that it is reiterating its Buy rating and $11.00 price target on Anixa Biosciences. The firm indicated that it arrived at its 12-month target price based upon an estimated total market value for Anixa of $363M (million) and projections for 32.6M common shares outstanding at the end of Q3/23.
Anixa Biosciences Inc. shares trade on the Nasdaq Exchange under the symbol "ANIX" and last closed for trading at $3.28 on Tuesday, July 26, 2022. The company has approximately 30.47M shares outstanding and a market cap of around $102.99M.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Disclosures
1) Steve Hytha wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. They or members of their household own securities of the following companies mentioned in the article: none. They or members of their household are paid by the following companies mentioned in this article: none.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with: None. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees, and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures for H.C. Wainwright & Co., Anixa Biosciences Inc., July 22, 2022
H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Yi Chen, Ph.D. CFA and Raghuram Selvaraju, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst’s household has a financial interest in the securities of Anixa Biosciences, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of June 30, 2022 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Anixa Biosciences, Inc..
Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.
The firm or its affiliates received compensation from Anixa Biosciences, Inc. for non-investment banking services in the previous 12 months.
The Firm or its affiliates did not receive compensation from Anixa Biosciences, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
The Firm does not make a market in Anixa Biosciences, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited.
This research report is not intended to provide tax advice or to be used to provide tax advice to any person.
H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.
H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice.
Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.
